Expert opinion in biological therapy: update on developments in lung gene transfer

被引:18
|
作者
Griesenbach, Uta [3 ]
Alton, Eric W. F. W. [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Gene Therapy, London SW3 6LR, England
[2] UK Cyst Fibrosis Gene Therapy Consortium, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Gene Therapy, London SW3 6LR, England
关键词
acute lung injury; airways; alpha 1-antitrypsin deficiency; asthma; chronic obstructive pulmonary disease; cystic fibrosis; gene therapy; lung infection; lung transplantation; non-viral gene transfer agents; primary ciliary dyskinesia; surfactant protein B deficiency; viral gene transfer agents; TRANSMEMBRANE CONDUCTANCE REGULATOR; RECOMBINANT ADENOASSOCIATED VIRUS; SUSTAINED TRANSGENE EXPRESSION; KERATINOCYTE GROWTH-FACTOR; CPG-FREE PLASMIDS; CYSTIC-FIBROSIS; AIRWAY EPITHELIUM; IN-VIVO; SENDAI-VIRUS; DIRECTED EVOLUTION;
D O I
10.1517/14712598.2013.735656
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Gene therapy may be suitable for a large number of acquired and inherited lung diseases, and research efforts in the field are vast. Although gene transfer to the lung has proven more challenging than initially anticipated, significant progress has been made over the last 10 years. Areas covered: Here, we will first review viral and non-viral gene transfer agents that have been assessed for lung gene therapy and discuss key barriers to pulmonary gene transfer. We will then review progress in gene therapy for various lung diseases. Expert opinion: In our view, one of the most significant developments in recent years is the generation of lentiviral vectors which efficiently transduce lung tissue. Focused and coordinated efforts assessing lentivirus safety and scaling up lentivirus production will be required to move this vector into clinical lung gene therapy studies. Although market authorization for a lung gene therapy product is not yet available, we are optimistic that this key milestone can be achieved in the next few years.
引用
收藏
页码:345 / 360
页数:16
相关论文
共 50 条
  • [1] Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease
    Griesenbach, Uta
    Alton, Eric W. F. W.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (05) : 642 - 662
  • [2] Gene therapy for acute lung injury
    K. L. Brigham
    A. A. Stecenko
    Intensive Care Medicine, 2000, 26 : S119 - S123
  • [3] Gene therapy for acute lung injury
    Brigham, KL
    Stecenko, AA
    INTENSIVE CARE MEDICINE, 2000, 26 (Suppl 1) : S119 - S123
  • [4] Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways
    Cmielewski, Patricia
    Farrow, Nigel
    Devereux, Sharnna
    Parsons, David
    Donnelley, Martin
    EXPERIMENTAL LUNG RESEARCH, 2017, 43 (9-10) : 426 - 433
  • [5] Update on gene therapy for cystic fibrosis
    Griesenbach, U
    Geddes, DM
    Alton, EWFW
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2003, 5 (05) : 489 - 494
  • [6] Commentary: Expert Opinion to "Imaging Bronchopulmonary Dysplasia-A Multimodality Update"
    Wielpuetz, Mark O.
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] Gene transfer to the lung: Lessons learned from more than 2 decades of CF gene therapy
    Griesenbach, Uta
    Alton, Eric W. F. W.
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (02) : 128 - 139
  • [8] Lessons learned from lung and liver in-vivo gene therapy: implications for the future
    van Haasteren, Joost
    Hyde, Stephen C.
    Gill, Deborah R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (09) : 959 - 972
  • [9] Gene Therapy Approaches to Biological Pacemakers
    Farraha, Melad
    Kumar, Saurabh
    Chong, James
    Cho, Hee Cheol
    Kizana, Eddy
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2018, 5 (04)
  • [10] Multifunctional nanocomplexes for gene transfer and gene therapy
    Hart, Stephen L.
    CELL BIOLOGY AND TOXICOLOGY, 2010, 26 (01) : 69 - 81